Clinical Research Directory
Browse clinical research sites, groups, and studies.
Epidiolex in Obsessive Compulsive Disorder and Related Disorders
Sponsor: University of Chicago
Summary
The primary objective of the proposed study is to evaluate the safety and efficacy of Epidiolex (cannabidiol) in adults with obsessive compulsive and related disorders (OCRDs). Subjects will be treated in an open-label fashion with Epidiolex for two weeks.
Official title: An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
4
Start Date
2022-04-14
Completion Date
2025-11-01
Last Updated
2026-07-29
Healthy Volunteers
No
Conditions
Interventions
Cannabidiol
Epidiolex oral solution (2.5 mg/kg and 5 mg/kg)
Locations (1)
University of Chicago
Chicago, Illinois, United States